{"schema_version":"secwatch.filing_event.v1","accession":"0001401521-24-000074","form_type":"8-K","ticker":"ACIC","cik":"0001401521","company_name":"AMERICAN COASTAL INSURANCE Corp","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.250030+00:00","generated_at":"2026-06-01T19:46:59.302082+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Stockholders approve 2020 Omnibus Incentive Plan and elect five Class B directors","bullets":["Plan approved with 29.3M for, 295k against; authorizes 4,000,000 shares for equity awards.","Five Class B directors elected for two-year terms: Alec L. Poitevint II, Kern M. Davis M.D., William H. Hood III, Sherrill W. Hudson, Patrick F. Maroney.","Deloitte & Touche ratified as independent auditor for 2024 with 39.5M for (99.95% of votes cast).","A total of 39.7M shares (83.0% of outstanding) present or represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001401521-24-000074","json":"https://secwatch.observer/filing/0001401521-24-000074.json","markdown":"https://secwatch.observer/filing/0001401521-24-000074.md","text":"https://secwatch.observer/filing/0001401521-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/uihc-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:46:59.302082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28df3cd7203eaf93da96dc92f7b3f319b6e220eb","claim":"AMERICAN COASTAL INSURANCE Corp shareholders approved Approval of the Plan.","evidence_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","confidence":0.99},{"claim_id":"734bf59bf865d0b44ead1346f0da2b060aa3f25f","claim":"AMERICAN COASTAL INSURANCE Corp shareholders approved Ratification of Deloitte & Touche, LLP as independent registered public accounting firm at the 2024-12-31 meeting.","evidence_excerpt":"Proposal Three: The stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2024. For Against Abstained Broker Non Votes 39,542,668 19,705 122,444 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","confidence":0.99},{"claim_id":"f595ceae21761530b6ed5fe66b48e82b395fdfab","claim":"AMERICAN COASTAL INSURANCE Corp shareholders approved Election of five Class B directors.","evidence_excerpt":"Proposal One: The stockholders elected each of the five persons named below to serve as Class B directors for a two-year term until the Company's 2026 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation, or removal. For Against Abstained Broker Non Votes Class B Directors Alec L. Poitevint, II 29,151,651 464,051 61,973 10,007,142 Kern M. Davis, M.D. 23,573,349 6,045,757 58,569 10,007,142 William H. Hood, III 29,537,183 80,473 60,019 10,007,142 Sherrill W. Hudson 29,300,586 316,999 60,090 10,007,142 Patrick F. Maroney 29,529,678 86,079 61,918 10,007,142","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","confidence":0.99}],"comparable_filings":[{"accession":"0001108524-26-000131","ticker":"CRM","company_name":"Salesforce, Inc.","filed_at":"2026-06-01T20:43:09+00:00","headline":"Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected","event_type":"other_material","sec_items":["5.07","5.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108524-26-000131","json":"https://secwatch.observer/filing/0001108524-26-000131.json","markdown":"https://secwatch.observer/filing/0001108524-26-000131.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/0001108524-26-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/crm-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"Advisory vote to approve the fiscal 2026 compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 493,864,228 117,716,717 668,510 102,463,325","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/0001108524-26-000131-index.htm"}},{"accession":"0000790816-26-000019","ticker":null,"company_name":"BRANDYWINE OPERATING PARTNERSHIP, L.P.","filed_at":"2026-06-01T20:30:42+00:00","headline":"Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP","event_type":"other_material","sec_items":["1.01","2.03","5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000790816-26-000019","json":"https://secwatch.observer/filing/0000790816-26-000019.json","markdown":"https://secwatch.observer/filing/0000790816-26-000019.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/790816/000079081626000019/bdn-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"PROPOSAL 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for calendar year 2026. Votes For Votes Against Abstentions 134,853,955 7,100,190 646,621","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm"}},{"accession":"0000908937-26-000015","ticker":"SIRI","company_name":"SIRIUS XM HOLDINGS INC.","filed_at":"2026-06-01T20:28:55+00:00","headline":"Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000908937-26-000015","json":"https://secwatch.observer/filing/0000908937-26-000015.json","markdown":"https://secwatch.observer/filing/0000908937-26-000015.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/0000908937-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/siri-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"Item 2 – Advisory Vote on Named Executive Officer Compensation The holders of our common stock approved, on a non-binding advisory basis, the compensation paid to our named executive officers. Votes Cast For Votes Cast Against Abstentions Broker Non-Votes 228,280,853 4,764,836 1,349,137 51,448,019","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/0000908937-26-000015-index.htm"}},{"accession":"0001628280-26-039518","ticker":"ESPR","company_name":"Esperion Therapeutics, Inc.","filed_at":"2026-06-01T20:22:15+00:00","headline":"Esperion shareholders approve 7M-share increase to 2022 equity incentive plan","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039518","json":"https://secwatch.observer/filing/0001628280-26-039518.json","markdown":"https://secwatch.observer/filing/0001628280-26-039518.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm"}},{"accession":"0000092380-24-000094","ticker":"LUV","company_name":"SOUTHWEST AIRLINES CO","filed_at":"2024-05-20T23:59:59+00:00","headline":"Southwest shareholders approve amended equity plan with 4.75M share increase; all directors elected","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000092380-24-000094","json":"https://secwatch.observer/filing/0000092380-24-000094.json","markdown":"https://secwatch.observer/filing/0000092380-24-000094.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/0000092380-24-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/luv-20240515.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"3. Proposal 3 – Approval of the Southwest Airlines Co. Amended and Restated 2007 Equity Incentive Plan: VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 408,346,613 28,870,401 1,635,532 90,613,942","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/0000092380-24-000094-index.htm"}},{"accession":"0001193125-24-141703","ticker":null,"company_name":"Regulus Therapeutics Inc.","filed_at":"2024-05-17T23:59:59+00:00","headline":"Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-141703","json":"https://secwatch.observer/filing/0001193125-24-141703.json","markdown":"https://secwatch.observer/filing/0001193125-24-141703.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/d829869d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm"}},{"accession":"0001628280-24-024025","ticker":"OSUR","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2024-05-17T23:59:59+00:00","headline":"OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability","event_type":"other_material","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-024025","json":"https://secwatch.observer/filing/0001628280-24-024025.json","markdown":"https://secwatch.observer/filing/0001628280-24-024025.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/0001628280-24-024025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/osur-20240514.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/0001628280-24-024025-index.htm"}},{"accession":"0001079973-24-000772","ticker":null,"company_name":"Nemaura Medical Inc.","filed_at":"2024-05-17T23:59:59+00:00","headline":"Shareholders approve reverse stock split authorization at ratio of 1:10 to 1:150","event_type":"other_material","sec_items":["5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000772","json":"https://secwatch.observer/filing/0001079973-24-000772.json","markdown":"https://secwatch.observer/filing/0001079973-24-000772.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/0001079973-24-000772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/nmra_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal Two: The stockholders vote to approve the Plan. For Against Abstained Broker Non Votes 29,307,066 295,204 75,405 10,007,142","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1401521/000140152124000074/0001401521-24-000074-index.htm","comparable_excerpt":"On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/0001079973-24-000772-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}